NEW YORK, NY / ACCESSWIRE / March 28, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: May 28, 2021 - November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
Throughout the class period, Fennec Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in FENC: https://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?id=25253&from=1
Cerence Inc. (NASDAQ:CRNC)
Class Period: February 8, 2021 - February 4, 2022
Lead Plaintiff Deadline: April 26, 2022
Cerence Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence's software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company's software licenses by pulling forward sales; and (3) as a result of the above, defendants' statements about Cerence's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in CRNC: https://www.kleinstocklaw.com/pslra-1/cerence-inc-loss-submission-form?id=25253&from=1
Cabaletta Bio, Inc. (NASDAQ:CABA)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive.
Lead Plaintiff Deadline: April 29, 2022
The complaint alleges Cabaletta Bio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in CABA: https://www.kleinstocklaw.com/pslra-1/cabaletta-bio-inc-loss-submission-form?id=25253&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm